Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ.

Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14. Erratum in: Lancet Haematol. 2018 Jun;5(6):e240.

PMID:
29550382
2.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
3.

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).

Ugolini A, Kenigsberg M, Rak A, Vallée F, Houtmann J, Lowinski M, Capdevila C, Khider J, Albert E, Martinet N, Nemecek C, Grapinet S, Bacqué E, Roesner M, Delaisi C, Calvet L, Bonche F, Semiond D, Egile C, Goulaouic H, Schio L.

J Med Chem. 2016 Aug 11;59(15):7066-74. doi: 10.1021/acs.jmedchem.6b00280. Epub 2016 Jul 13.

PMID:
27355974
4.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
5.

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.

Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF.

Neuro Oncol. 2015 Sep;17(9):1275-83. doi: 10.1093/neuonc/nov083. Epub 2015 May 26.

6.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT.

Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.

7.

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S.

Gynecol Oncol. 2015 Feb;136(2):246-53. doi: 10.1016/j.ygyno.2014.12.019. Epub 2014 Dec 17.

PMID:
25528496
8.

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.

Egile C, Kenigsberg M, Delaisi C, Bégassat F, Do-Vale V, Mestadier J, Bonche F, Bénard T, Nicolas JP, Valence S, Lefranc C, Francesconi E, Castell C, Lefebvre AM, Nemecek C, Calvet L, Goulaouic H.

Mol Cancer Ther. 2015 Feb;14(2):384-94. doi: 10.1158/1535-7163.MCT-14-0428. Epub 2014 Dec 10.

9.

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.

Papadopoulos KP, Egile C, Ruiz-Soto R, Jiang J, Shi W, Bentzien F, Rasco D, Abrisqueta P, Vose JM, Tabernero J.

Leuk Lymphoma. 2015 Jun;56(6):1763-70. doi: 10.3109/10428194.2014.974040. Epub 2014 Nov 19.

PMID:
25300944
10.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM.

Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.

11.

MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma.

Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, Castell C, Larois C, Micallef S, Saulnier P, Goulaouic H, Lefebvre AM, Temam S.

PLoS One. 2014 Jan 17;9(1):e84319. doi: 10.1371/journal.pone.0084319. eCollection 2014.

12.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G.

Clin Cancer Res. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Epub 2013 Oct 28. Erratum in: Clin Cancer Res. 2015 May 1;21(9):2192.

13.

Three-dimensional reconstructions of Arp2/3 complex with bound nucleation promoting factors.

Xu XP, Rouiller I, Slaughter BD, Egile C, Kim E, Unruh JR, Fan X, Pollard TD, Li R, Hanein D, Volkmann N.

EMBO J. 2012 Jan 4;31(1):236-47. doi: 10.1038/emboj.2011.343. Epub 2011 Sep 20.

14.

The structural basis of actin filament branching by the Arp2/3 complex.

Rouiller I, Xu XP, Amann KJ, Egile C, Nickell S, Nicastro D, Li R, Pollard TD, Volkmann N, Hanein D.

J Cell Biol. 2008 Mar 10;180(5):887-95. doi: 10.1083/jcb.200709092. Epub 2008 Mar 3.

15.

IQGAP1 stimulates actin assembly through the N-WASP-Arp2/3 pathway.

Le Clainche C, Schlaepfer D, Ferrari A, Klingauf M, Grohmanova K, Veligodskiy A, Didry D, Le D, Egile C, Carlier MF, Kroschewski R.

J Biol Chem. 2007 Jan 5;282(1):426-35. Epub 2006 Nov 2.

16.

Characterization of TccP-mediated N-WASP activation during enterohaemorrhagic Escherichia coli infection.

Garmendia J, Carlier MF, Egile C, Didry D, Frankel G.

Cell Microbiol. 2006 Sep;8(9):1444-55.

PMID:
16922863
17.

Interaction of N-WASP with hnRNPK and its role in filopodia formation and cell spreading.

Yoo Y, Wu X, Egile C, Li R, Guan JL.

J Biol Chem. 2006 Jun 2;281(22):15352-60. Epub 2006 Mar 30.

18.

NMR analyses of the activation of the Arp2/3 complex by neuronal Wiskott-Aldrich syndrome protein.

Kreishman-Deitrick M, Goley ED, Burdine L, Denison C, Egile C, Li R, Murali N, Kodadek TJ, Welch MD, Rosen MK.

Biochemistry. 2005 Nov 22;44(46):15247-56.

PMID:
16285728
19.

Mechanism of filament nucleation and branch stability revealed by the structure of the Arp2/3 complex at actin branch junctions.

Egile C, Rouiller I, Xu XP, Volkmann N, Li R, Hanein D.

PLoS Biol. 2005 Nov;3(11):e383. Epub 2005 Nov 8.

20.

Cortactin regulates cell migration through activation of N-WASP.

Kowalski JR, Egile C, Gil S, Snapper SB, Li R, Thomas SM.

J Cell Sci. 2005 Jan 1;118(Pt 1):79-87. Epub 2004 Dec 7.

21.

Activation of Arp2/3 complex-dependent actin polymerization by plant proteins distantly related to Scar/WAVE.

Frank M, Egile C, Dyachok J, Djakovic S, Nolasco M, Li R, Smith LG.

Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16379-84. Epub 2004 Nov 8.

22.

Formin is a processive motor that requires profilin to accelerate actin assembly and associated ATP hydrolysis.

Romero S, Le Clainche C, Didry D, Egile C, Pantaloni D, Carlier MF.

Cell. 2004 Oct 29;119(3):419-29.

23.
24.

The RickA protein of Rickettsia conorii activates the Arp2/3 complex.

Gouin E, Egile C, Dehoux P, Villiers V, Adams J, Gertler F, Li R, Cossart P.

Nature. 2004 Jan 29;427(6973):457-61.

25.

NMR analysis of methyl groups at 100-500 kDa: model systems and Arp2/3 complex.

Kreishman-Deitrick M, Egile C, Hoyt DW, Ford JJ, Li R, Rosen MK.

Biochemistry. 2003 Jul 22;42(28):8579-86.

PMID:
12859205
26.

Tir - Nck's new afficionado.

Egile C.

Trends Cell Biol. 2001 Dec;11(12):461. No abstract available.

PMID:
11719035
27.

Structure of Arp2/3 complex in its activated state and in actin filament branch junctions.

Volkmann N, Amann KJ, Stoilova-McPhie S, Egile C, Winter DC, Hazelwood L, Heuser JE, Li R, Pollard TD, Hanein D.

Science. 2001 Sep 28;293(5539):2456-9. Epub 2001 Aug 30.

28.

Activation of Arp2/3 complex-mediated actin polymerization by cortactin.

Uruno T, Liu J, Zhang P, Fan Yx, Egile C, Li R, Mueller SC, Zhan X.

Nat Cell Biol. 2001 Mar;3(3):259-66.

PMID:
11231575
29.

Diversion of cytoskeletal processes by Shigella during invasion of epithelial cells.

Bourdet-Sicard R, Egile C, Sansonetti PJ, Tran Van Nhieu G.

Microbes Infect. 2000 Jun;2(7):813-9. Review.

PMID:
10955962
30.

GRB2 links signaling to actin assembly by enhancing interaction of neural Wiskott-Aldrich syndrome protein (N-WASp) with actin-related protein (ARP2/3) complex.

Carlier MF, Nioche P, Broutin-L'Hermite I, Boujemaa R, Le Clainche C, Egile C, Garbay C, Ducruix A, Sansonetti P, Pantaloni D.

J Biol Chem. 2000 Jul 21;275(29):21946-52.

31.

Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility.

Egile C, Loisel TP, Laurent V, Li R, Pantaloni D, Sansonetti PJ, Carlier MF.

J Cell Biol. 1999 Sep 20;146(6):1319-32.

32.
33.

Rho family GTPases control entry of Shigella flexneri into epithelial cells but not intracellular motility.

Mounier J, Laurent V, Hall A, Fort P, Carlier MF, Sansonetti PJ, Egile C.

J Cell Sci. 1999 Jul;112 ( Pt 13):2069-80.

34.

A comparative study of the actin-based motilities of the pathogenic bacteria Listeria monocytogenes, Shigella flexneri and Rickettsia conorii.

Gouin E, Gantelet H, Egile C, Lasa I, Ohayon H, Villiers V, Gounon P, Sansonetti PJ, Cossart P.

J Cell Sci. 1999 Jun;112 ( Pt 11):1697-708.

35.

Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri.

Sansonetti PJ, Tran Van Nhieu G, Egile C.

Clin Infect Dis. 1999 Mar;28(3):466-75. Review.

PMID:
10194063
36.

Molecular bases of epithelial cell invasion by Shigella flexneri.

Sansonetti PJ, Egile C.

Antonie Van Leeuwenhoek. 1998 Nov;74(4):191-7. Review.

PMID:
10081579
37.

SopA, the outer membrane protease responsible for polar localization of IcsA in Shigella flexneri.

Egile C, d'Hauteville H, Parsot C, Sansonetti PJ.

Mol Microbiol. 1997 Mar;23(5):1063-73.

38.

Characterization of a monoclonal IgMK (IgMGAS) anti-Gd cold agglutinin (CA). Its coexistence with a monoclonal IgG3K (IgGGAS) without CA activity that might be clonally related to IgMGAS.

De la Fuente MA, Egile C, Pereira A, Juan M, Vivanco F, Roelcke D, Dighiero G, Gallart T.

Blood. 1994 Mar 1;83(5):1310-22.

PMID:
8118034
39.

V gene usage by seven hybrids derived from CD5+ B-cell chronic lymphocytic leukemia and displaying autoantibody activity.

Pritsch O, Magnac C, Dumas G, Egile C, Dighiero G.

Blood. 1993 Nov 15;82(10):3103-12.

PMID:
7693035

Supplemental Content

Support Center